Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MRG007 + bevacizumab
- Development stage
- Unknown
- Lead developer
- ArriVent BioPharma
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MRG007 + bevacizumab is an investigational combination therapy comprising MRG007 (also known as ARR-217) and bevacizumab. MRG007 is a cadherin-17 (CDH17)-targeted antibody-drug conjugate (ADC) that utilizes a glycan-linked, exatecan-based payload to deliver cytotoxic effects to cells overexpressing CDH17, a molecule frequently found in gastrointestinal malignancies. Bevacizumab is a recombinant humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking tumor angiogenesis. The combination is designed to leverage the targeted cytotoxicity of the ADC alongside the anti-angiogenic properties of bevacizumab to treat advanced solid tumors, particularly colorectal, gastric, and pancreatic cancers. The regimen is currently being evaluated in a Phase I clinical trial (NCT07066657) sponsored by ArriVent BioPharma.
- Other names
- MRG007 plus bevacizumabMRG-007 plus bevacizumabMRG 007 plus bevacizumab
02
Targets
Beyond the preview
Go deeper on MRG007 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MRG007 + bevacizumab.